Next Article in Journal
NeuroHeal Reduces Muscle Atrophy and Modulates Associated Autophagy
Previous Article in Journal
Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State
Previous Article in Special Issue
TLR2 and Dectin-1 Signaling in Mouse Hematopoietic Stem and Progenitor Cells Impacts the Ability of the Antigen Presenting Cells They Produce to Activate CD4 T Cells
Open AccessArticle

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer

1
Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad Autónoma de Buenos Aires C1426AOE, Argentina
2
Fundación Instituto Leloir, Ciudad Autónoma de Buenos Aires C1405BWE, Argentina
3
Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires C1426AOE, Argentina
*
Author to whom correspondence should be addressed.
Cells 2020, 9(7), 1573; https://doi.org/10.3390/cells9071573
Received: 29 January 2020 / Revised: 12 June 2020 / Accepted: 15 June 2020 / Published: 28 June 2020
(This article belongs to the Special Issue Dendritic Cells in Immunity and Inflammation)
Triple Negative Breast Cancer (TNBC) treatment is still challenging, and immunotherapy is a potential approach in this tumor subtype. Cetuximab is an IgG1 monoclonal antibody (mAb) directed against Epidermic Growth Factor Receptor (EGFR), a protein overexpressed in a subgroup of TNBC patients and associated with poor prognosis. Previously, we demonstrated in vitro that Cetuximab triggers Ab-dependent cell cytotoxicity against TNBC cells. In this study, using co-cultures including TNBC cells, and NK and Dendritic Cells (DCs) from healthy donors, we studied the effect of Cetuximab-activated NK cells on DC function. Given that we already demonstrated that TNBC has an immunosuppressive effect on NK cells, we also tested Cetuximab combination with IL-15. We determined that Cetuximab opsonization of TNBC cells increased IFN-γ and TNF-α production by NK cells co-cultured with DCs. Moreover, we showed that NK cells activated by TNBC cells opsonized with Cetuximab promoted tumor material uptake and maturation of DCs, as well as their ability to produce IL-12. Furthermore, the stimulation with IL-15 increased the activation of NK cells and the maturation of DCs. These results suggest that IL-15 may enhance the efficacy of Cetuximab in the treatment of TNBC by promoting activation of both NK cells and DCs. View Full-Text
Keywords: NK cells; dendritic cells; ADCC; Cetuximab; triple negative breast cancer NK cells; dendritic cells; ADCC; Cetuximab; triple negative breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Juliá, E.P.; Mordoh, J.; Levy, E.M. Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer. Cells 2020, 9, 1573.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop